^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners

COMPANY:
Veracyte

i
Other names: Veracyte, Inc. | Veracyte | Veracyte Inc. | Veracyte Inc | Veracyte, Inc | Calderome, Inc. | Decipher Biosciences | GenomeDx Biosciences | GenomeDx | Decipher Biosciences, Inc. | Decipher Biosciences Inc. | Decipher Biosciences, Inc | GenomeDx Biosciences, Inc. | HalioDx | HalioDx, Inc. | HalioDx Inc | HalioDx Inc. | HalioDx SAS | HalioDx SASU
Related tests:
Evidence

News

2ms
Veracyte’s Decipher Prostate Test Receives Highest Evidence-Level Rating Among Molecular Tests in Updated Prostate Cancer NCCN Guidelines (Businesswire)
"Veracyte...announced that its Decipher Prostate Genomic Classifier is the only gene expression test to receive a 'Level 1B' evidence rating in the 2024 NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) as a prognostic tool for the risk stratification of patients with localized prostate cancer. Level 1B was assigned to Decipher Prostate based on the evidence in both the post-biopsy and post-prostatectomy settings. Additionally, because of this classification, the Decipher Prostate test is the only gene expression test for which the guidelines synthesize the available published data in a separate table that summarizes treatment implications for patients based on both their NCCN risk classification and Decipher score."
NCCN guideline
|
Decipher Prostate Cancer Test
2ms
Veracyte completes acquisition of C2i Genomics (Veracyte Press Release)
"Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced it has completed its acquisition of C2i Genomics, Inc., adding whole-genome minimal residual disease (MRD) capabilities to its novel diagnostics platform and expanding the company’s ability to serve patients across the cancer care continuum."
M&A
3ms
Veracyte announces preliminary full-year 2023 results, acquisition of C2i Genomics to add Minimal Residual Disease capabilities to its novel diagnostics platform (Veracyte Press Release)
"The company also announced it has reached a definitive agreement to acquire C2i Genomics, Inc. a minimal residual disease (MRD) detection company, adding whole-genome MRD capabilities to its novel diagnostics platform and positioning Veracyte to expand its offerings along the cancer care continuum. Under the terms of the agreement, Veracyte will pay $70 million in Veracyte shares at closing, and up to an additional $25 million based on the achievement of future performance milestones over the next two years, payable in Veracyte shares or cash at Veracyte’s election."
M&A
5ms
Real-world data presented at SUO 2023 show that Veracyte’s Decipher Genomic Classifier identifies patients whose prostate cancer is likely to progress (Veracyte Press Release)
"Veracyte...announced that new data presented today at the 24th Annual Meeting of the Society of Urologic Oncology (SUO 2023) highlight clinical observations and translational research conducted by users of the company’s Decipher Prostate Genomic Classifier. These independent, real-world studies provide further evidence supporting the clinical utility of the test in the treatment and management of prostate cancer, particularly for patients considering active surveillance."
Real-world evidence
|
Decipher Prostate Cancer Test
5ms
Clinical validation data published in CHEST demonstrate that Veracyte’s Percepta Nasal Swab test improves lung cancer risk assessment for patients with lung nodules (Veracyte Press Release)
"Veracyte...announced that clinical validation data published in the journal CHEST show that the company’s Percepta Nasal Swab test determines lung cancer risk, with high accuracy, among people who currently smoke or have previously smoked and have lung nodules. The findings suggest that the novel, non-invasive genomic test can help physicians guide next steps for these patients, enabling them to potentially avoid unnecessary invasive procedures or accelerate time to appropriate treatment."
Clinical data
5ms
Veracyte Announces Seven Posters Highlighting Clinical Value of Decipher Prostate Genomic Testing To be Presented at SUO 2023 (Businesswire)
"Veracyte, Inc...announced that seven posters will be presented at the 24th Annual Meeting of the Society of Urologic Oncology (SUO 2023), where they will demonstrate the clinical performance of Veracyte’s Decipher Prostate Genomic Classifier in identifying patients whose prostate cancer is likely to progress and require treatment. Collectively, the posters will report data from more than 60,000 patients. The meeting will take place in Washington, DC, from November 28 to December 1."
Clinical data
|
Decipher Prostate Cancer Test
5ms
Veracyte announces in vitro diagnostic agreement with Illumina to broaden availability of its tests for patients globally (Veracyte Press Release)
"Veracyte...announced that it has entered into a multi-year agreement with Illumina...to develop and offer some of its high-performing molecular tests as decentralized in vitro diagnostic (IVD) tests on Illumina’s NextSeq 550Dx next-generation sequencing (NGS) instrument...The first tests that Veracyte plans to develop for the Illumina NextSeq 550Dx instrument are its Prosigna Breast Cancer Assay and Percepta Nasal Swab test. Prosigna is already commercially available as an IVD test that helps inform treatment decisions for patients with early-stage breast cancer."
Licensing / partnership
|
Prosigna™ Breast Cancer Prognostic Gene Signature Assay
6ms
Veracyte Announces SITC 2023 Presentations Offering New Insight into Immuno-oncology Drug Development (Businesswire)
"Veracyte, Inc...today announced that two poster presentations taking place at SITC 2023, the annual meeting of the Society for Immunotherapy of Cancer, in San Diego from November 3-5 will demonstrate the potential for using the company’s novel tools to help advance the development of immuno-oncology drugs. These tools allow for better characterization of the tumor microenvironment (TME), which can enable new insights into drug response and mechanisms of resistance....'These conference presentations will show that Veracyte’s Brightplex and Immunoscore IC tools can offer scientists a clearer view of the tumor microenvironment, as well as data that could inform immuno-oncology drug development.'"
Clinical
|
Immunoscore® IC Assay
6ms
C2i Genomics and OncoDNA begin molecular residual disease testing across Europe (OncoDNA Press Release)
"OncoDNA...announced the next stage in its partnership with C2i Genomics...The lab uses C2inform, the first CE-IVDD marked software-as-a-medical-device molecular residual disease (MRD) test."
Licensing / partnership
|
C2inform test
6ms
New data from phase 3 trial further validate prognostic value of Veracyte’S Decipher Prostate Genomic Classifier (Veracyte Press Release)
"Veracyte...announced that new data from a large, randomized phase 3 trial reinforce the value of the Decipher Prostate Genomic Classifier in helping physicians make more informed treatment decisions for their patients with prostate cancer. The findings, presented at the 2023 American Society for Radiation Oncology (ASTRO) Annual Meeting, suggest that the Decipher Prostate test can categorize more accurately risk of patients with clinically high-risk disease to help inform appropriate treatment."
Clinical data
|
Decipher Prostate Cancer Test
7ms
Veracyte announces multiple studies reinforcing the value of decipher prostate testing will be presented at ASTRO 2023 (Veracyte Press Release)
"Veracyte...announced that six abstracts highlighting new data from studies evaluating the company’s Decipher Prostate Genomic Classifier and related capabilities will be presented, three as oral presentations, at the American Society for Radiation Oncology (ASTRO) Annual Meeting 2023 taking place October 1-4 in San Diego."
Clinical data
|
Decipher Prostate Cancer Test
7ms
New data presented at the 2023 ATA annual meeting demonstrate that Veracyte’s Afirma-based testing can uncover key molecular hallmarks of thyroid cancer (Veracyte Press Release)
"Veracyte...announced that six abstracts highlighting new data from studies evaluating the company’s Decipher Prostate Genomic Classifier and related capabilities will be presented, three as oral presentations, at the American Society for Radiation Oncology (ASTRO) Annual Meeting 2023 taking place October 1-4 in San Diego."
Clinical data
|
Afirma® Genomic Sequencing Classifier
7ms
Veracyte announces novel Afirma-based findings that advance molecular understanding of thyroid cancer to be presented at the 2023 ATA annual meeting (Veracyte Press Release)
"Veracyte...announced that three posters showcasing new data from the company’s Afirma Genomic Sequencing Classifier (GSC) will be presented at the 2023 American Thyroid Association (ATA) Annual Meeting being held in Washington, DC from September 27 to October 1. Together, these abstracts offer novel insights into the molecular underpinnings of thyroid nodules and tumors based on whole-transcriptome RNA sequencing data from thyroid nodules analyzed with the Afirma GSC."
Clinical data
|
Afirma® Genomic Sequencing Classifier
8ms
Veracyte Announces that Findings Published in JCO Precision Oncology Suggest Potential of Decipher GRID-Derived Gene Signatures to Predict Treatment Response in Recurrent Prostate Cancer (Businesswire)
P2 | N=38 | STREAM (NCT02057939) | "The findings, from the Phase 2 STREAM study, suggest the potential to use transcriptomic signatures to identify patients in this setting who may benefit from more intensive salvage therapy as well as those who may need alternative care such as chemotherapy....Results suggest that patients in the study who experienced shorter progression-free survival (PFS) over three years had a luminal proliferating tumor subtype, loss of the PTEN gene and/or higher homologous recombination deficiency (HRD) signature scores. Patients with luminal differentiated or luminal A-type tumors and/or higher postoperative ADT responsiveness genomic signature scores were more likely to have durable responses and long-term remissions with the aggressive systemic regimen of ADT and enzalutamide combined with salvage radiotherapy."
P2 data
|
Xtandi (enzalutamide capsule)
8ms
C2i Genomics and Ichilov join forces to bring cancer detection and monitoring platform to Israel (Webwire)
"C2i Genomics...announced its strategic collaboration with the Tel Aviv Sourasky Medical Center (Ichilov)...Together, the organizations will provide precision oncology clinical testing using C2inform, C2i Genomics’ whole genome minimal residual disease (MRD) test to improve cancer detection and monitoring nationwide."
Licensing / partnership
|
C2inform test
9ms
Study Published in JNCI Cancer Spectrum Demonstrates Real-World Utility of Veracyte’s Decipher Prostate Genomic Classifier in Prostate Cancer Treatment (Businesswire)
"Veracyte, Inc...announced the publication of a large, real-world study reinforcing the Decipher Prostate Genomic Classifier’s ability to guide personalized treatment approaches for men with prostate cancer. The study utilized data from the first linkage of prostate cancer cases reported by central cancer registries participating in the Surveillance, Epidemiology, and End Results (SEER) Program, with Decipher test results....The results demonstrated that AS/WW was highest among subjects with low-risk Decipher biopsy results (41%), compared to those who had intermediate-risk (27%) or high-risk (11%) scores. Among subjects with clinically low-risk prostate cancer, 65% of those with low-risk Decipher results were managed with AS/WW."
Real-world evidence
|
Decipher Prostate Cancer Test
10ms
New data suggest Veracyte’s Afirma molecular testing capabilities can help advance scientific understanding of thyroid nodules and cancer (Veracyte Press Release)
"Veracyte...announced that new data presented at ENDO 2023, the annual meeting of The Endocrine Society, suggest the company’s Afirma molecular testing and whole-transcriptome capabilities can provide novel insights that may advance the scientific understanding of thyroid nodule biology. In addition, findings from an analytical validity study presented at the meeting show that the Afirma TERT promoter mutation test performs with high analytical sensitivity and specificity."
Clinical data
|
Afirma® Genomic Sequencing Classifier
10ms
Veracyte announces Afirma-focused abstracts to be presented at ENDO 2023 (Veracyte Press Release)
"Veracyte...announced that three abstracts highlighting new data on the company’s Afirma test and capabilities will be presented at ENDO 2023, the annual meeting of The Endocrine Society, which is taking place June 15-18 in Chicago, Ill. Additionally, Veracyte’s medical director of Endocrinology, Joshua Klopper, M.D., will participate in a symposium panel discussion on the advantages of various molecular testing approaches to help personalize and improve care for people with potentially cancerous thyroid nodules."
Clinical data
|
Afirma® Genomic Sequencing Classifier
11ms
New data to be shared at 2023 ASCO demonstrate power of Veracyte’s Decipher GRID to help advance molecular understanding of prostate cancer (Veracyte Press Release)
"Veracyte...announced that new data to be shared at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting demonstrate the ability of the company’s Decipher Genomics Resource for Intelligent Discovery (GRID) database to enable novel molecular insights into prostate cancer. The findings, from three separate studies, may ultimately help inform more personalized treatment for patients with prostate cancer."
Clinical data
11ms
New Data Presented at ATS 2023 Reinforce Clinical Utility of Veracyte’s Genomic Tests in Interstitial Lung Disease and Lung Cancer (Businesswire)
"Veracyte...today announced new data suggesting its novel genomic tests may positively impact diagnosis and care for patients being evaluated for interstitial lung disease (ILD) or lung cancer. The findings were presented at ATS 2023, the annual meeting of the American Thoracic Society, which is being held May 21-24 in Washington, D.C....An Envisia-positive result for UIP prompted an increase in use of anti-fibrotic drugs (from 11.9% to 71.4%), which are used to treat IPF and other progressive ILDs. An Envisia-positive result for UIP also led to a reduction in immuno-suppressant drugs (from 23.8% to 9.5%), which can be harmful to patients with IPF."
Clinical data
11ms
Veracyte Announces that New Data Show Use of the Prosigna Test Significantly Changed Treatment Decisions for Patients with Early-Stage Breast Cancer (Businesswire)
P=NA | N=2,164 | "Veracyte, Inc...announced that new data show the use of the Prosigna Breast Cancer Assay altered treatment decisions for patients with early-stage breast cancer, including significantly reducing the use of chemotherapy among those with clinically high-risk disease....These initial data focused on treatment decisions and were shared in a poster (#103P) today at ESMO Breast Cancer Congress 2023, taking place May 11-13 in Berlin....The researchers found that use of Prosigna changed adjuvant therapy decisions for almost one-third (29%) of patients. Notably, for patients assigned to chemotherapy prior to Prosigna results, 45% were de-escalated to endocrine therapy following Prosigna results."
Clinical data
|
Prosigna™ Breast Cancer Prognostic Gene Signature Assay
11ms
New data being presented at AACE 2023 help elucidate cancer risk of TERT promoter gene mutations in patients with indeterminate thyroid nodules (Veracyte Press Release)
"Veracyte...announced findings from a large-scale, systematic literature review showing that TERT promoter gene mutations in thyroid nodules deemed indeterminate by cytopathology are rare, but have a high risk of malignancy and, in certain cases, are associated with aggressive tumor behavior. The data are being presented at the American Association of Clinical Endocrinology (AACE) 2023 Annual Meeting, being held May 4-6 in Seattle, and reinforce the value of Veracyte’s expanded Afirma offering, which now includes TERT promoter mutation testing."
Clinical data
12ms
New data published in cancer suggest Decipher GRID-derived gene expression signature could enable more personalized treatment for prostate cancer patients (Veracyte Press Release)
"Veracyte...announced that data published in the journal Cancer show the ability of a novel gene expression signature to classify prostate cancer into distinct molecular subtypes that may inform which tumors are more likely to respond to different treatments. The findings suggest that the novel biomarker, derived largely using Veracyte’s Decipher Genomics Resource for Intelligent Discovery (GRID) database, could potentially enable physicians to further personalize care for their patients with prostate cancer."
Clinical data
12ms
Data published in "The Red Journal” validate clinical utility of Veracyte’s Decipher Prostate Genomic Classifier to help guide therapy in men with intermediate-risk prostate cancer (Veracyte Press Release)
"Veracyte...announced that data published in the International Journal of Radiation Oncology, Biology, Physics (aka, 'The Red Journal') validate the clinical utility of the company’s Decipher Prostate Genomic Classifier for helping to guide treatment selection in men with intermediate-risk prostate cancer. The findings are from NRG Oncology/RTOG 0126, a Phase 3 randomized clinical trial of patients with intermediate-risk prostate cancer treated with definitive radiotherapy without concomitant hormone therapy. This is the first randomized study to validate any gene-expression biomarker in this patient population, adding further evidence to support the Decipher Prostate test’s utility."
Clinical data
|
Decipher Prostate Cancer Test
12ms
Three abstracts focusing on the clinical utility of Veracyte’s genomic tests in ILD and lung cancer to be presented at ATS 2023 International conference (Veracyte Press Release)
"Veracyte...announced that three abstracts focused on the company’s genomic tests for interstitial lung disease (Envisia Genomic Classifier) and lung cancer (Percepta Nasal Swab) will be presented at the American Thoracic Society (ATS) 2023 International Conference. The meeting will take place May 19-24 in Washington, D.C."
Clinical data
12ms
Findings from two large-scale, real-world data sets reinforce clinical utility of Veracyte’s Decipher Prostate Genomic Classifier (Veracyte Press Release)
"Veracyt...announced that new data presented at the American Urological Association (AUA) 2023 Annual Meeting validate the real-world performance and clinical utility of the company’s Decipher Prostate Genomic Classifier. The findings are from two separate, large-scale studies evaluating the Decipher Prostate test among a total of more than 100,000 individuals with prostate cancer and reinforce its role as a new standard of care to help inform treatment decisions for these patients."
Clinical data
|
Decipher Prostate Cancer Test
12ms
Veracyte Announces Five Abstracts Providing Molecular Insights Into Prostate and Other Cancers To Be Presented at the 2023 ASCO Annual Meeting (Businesswire)
"Veracyte...announced that five abstracts providing new molecular insights into prostate and other cancers will be presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place in Chicago and online June 2-6. Three of the accepted abstracts leverage Veracyte’s Decipher GRID (Genomic Resource for Intelligent Discovery) database to explore potential opportunities for further personalizing treatment for patients with prostate cancer."
Clinical data
|
Keytruda (pembrolizumab) • Tecentriq (atezolizumab) • Xtandi (enzalutamide capsule)
1year
New Data Reinforce Ability of Veracyte’s Decipher Prostate Genomic Classifier To Help Identify Prostate Cancer Patients Who Would Benefit from Treatment Intensification (Businesswire)
P=NA | N=NA | "Veracyte, Inc...announced that new data published in European Urology Oncology suggest the Decipher Prostate Genomic Classifier could help identify prostate cancer patients who have micrometastatic disease (difficult-to-detect tumor cells that extend beyond the prostate) and who may therefore benefit from systemic treatment intensification....The researchers found that there was a significant correlation between patients’ Decipher Prostate scores and the risk of upstaging on PSMA PET, and that high Decipher scores were especially enriched in patients at the highest risk of harboring disease outside their prostate."
Clinical data
|
Decipher Prostate Cancer Test
1year
Veracyte Announces Seven Abstracts for Its Decipher Urologic Cancer Tests To Be Presented at 2023 AUA Annual Meeting (Businesswire)
"Veracyte, Inc...announced today that seven abstracts highlighting new data from studies of the company’s Decipher urologic cancer tests will be presented at the American Urological Association (AUA) Annual Meeting, taking place April 28-May 1, 2023, at McCormick Place in Chicago. The abstracts include findings from two separate, large-scale studies that reinforce the real-world clinical utility of the company’s Decipher Prostate Genomic Classifier, which helps inform treatment decisions for men with prostate cancer."
Clinical
|
Decipher Bladder Test • Decipher Prostate Cancer Test
1year
Veracyte announces three abstracts to be presented at AACR annual meeting 2023 highlighting the company’s multi-omics capabilities and tools for biopharma partners (Veracyte Press Release)
"Veracyte...announced today that three abstracts highlighting the company’s unique, multi-omics capabilities and offerings for biopharmaceutical partners will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2023, taking place April 14-19, 2023, at the Orange County Convention Center in Orlando, Florida."
Clinical data
1year
C2i Genomics, Riken Genesis expand AI-powered cancer detection technology across Japan (Biospectrumasia)
"US-headquartered startup C2i Genomics has announced a collaboration with Riken Genesis (RG) Co. to bring minimal residual disease (MRD) cancer monitoring to Japan for pharmaceutical and clinical research...Under this agreement, RG will work with C2i Genomics to commercialise its C2intelligence cloud-based platform and the C2inform MRD test for pharmaceutical and clinical research and eventually for commercial clinical testing in Japan."
Licensing / partnership
|
C2inform test
1year
Data published in “The Red Journal” validate prognostic value of Veracyte’s Decipher Prostate Genomic Classifier for men with high-risk prostate cancer (Veracyte Press Release)
"Veracyte...announced that data published in the International Journal of Radiation Oncology, Biology, Physics (aka, 'The Red Journal') demonstrate that the company’s Decipher Prostate Genomic Classifier can improve risk stratification among men with clinically high-risk prostate cancer. The data, from a pre-specified analysis of three phase 3 trials, represent the first validation of any gene-expression biomarker on pre-treatment biopsy samples from prospective randomized trials, and suggest the Decipher test provides clinically useful prognostic information to help personalize shared treatment decision-making."
Clinical data
|
Decipher Prostate Cancer Test
1year
New data to be presented at 2023 ASCO GU suggest Decipher GRID-derived gene expression signature can help personalize prostate cancer treatment (Veracyte Press Release)
"Veracyte...announced new data being presented this week at the 2023 American Society of Clinical Oncology Genitourinary (ASCO GU) Symposium which demonstrate that a gene expression signature derived from the company’s proprietary Decipher Genomics Resource for Intelligent Discovery (GRID) database may help physicians further personalize treatment for men with prostate cancer, based on their tumor’s molecular subtype. Additional data being presented at the meeting, taking place in San Francisco and online, February 16-18, reinforce the clinical utility of the company’s Decipher Prostate Genomic Classifier."
Clinical data
|
Decipher Prostate Cancer Test
1year
Veracyte announces new data suggesting Afirma testing can help personalize care for patients with thyroid nodules (Veracyte Press Release)
"Veracyte...announced that data published in Frontiers in Endocrinology provide new insights into the frequency and risk of malignancy (ROM) associated with thyroid stimulating hormone receptor (TSHR) mutations in indeterminate thyroid nodules. The findings, which were derived from analyses of Veracyte’s comprehensive thyroid nodule database of whole transcriptome sequencing, suggest that the use of Afirma testing could help inform diagnoses and personalized treatment decisions for patients with thyroid nodules."
Clinical data
|
Afirma® Genomic Sequencing Classifier
1year
Veracyte Announces Multiple Decipher Urologic Testing Abstracts to be Presented at the 2023 ASCO Genitourinary (GU) Cancers Symposium (Businesswire)
"Veracyte, Inc...announced that six abstracts highlighting new data focused on the company’s Decipher urologic cancer testing offerings will be presented at the 2023 ASCO Genitourinary (GU) Cancers Symposium, taking place in San Francisco, Calif. and online, February 16-18, 2023. Data being presented include new insights derived from Veracyte’s Decipher Genomics Resource for Intelligent Discovery (GRID) database, which suggest potential opportunities to further personalize treatment for men with prostate cancer. Additionally, researchers will present new Decipher Prostate Genomic Classifier clinical utility data from the prospective, phase 3, randomized clinical trial, G-MINOR (Genomics in Michigan ImpactiNg Observation or Radiation)."
Clinical data • P2 data
|
Decipher Prostate Cancer Test
over1year
AstraZeneca to evaluate C2i Genomics' cancer detection, monitoring platform (Precision Medicine Online)
"AstraZeneca will evaluate C2i Genomics' whole-genome minimal residual disease assay and cancer-monitoring platform for use in clinical research and drug development efforts, the companies announced Thursday...The agreement is an extension of a previous collaboration in which the companies evaluated C2i Genomics' minimal residual disease (MRD) test across multiple solid cancers using artificially generated samples. The test was able to detect circulating tumor DNA (ctDNA), which was present at varying levels in the samples, down to 0.002 percent allelic frequency, the firms said."
Clinical
|
C2inform test
over1year
Data published in JCEM demonstrate strong real-world performance of Veracyte’s Afirma GSC in thyroid cancer diagnosis (Veracyte Press Release)
"Veracyte...announced that findings demonstrating the strong real-world performance of the Afirma Genomic Sequencing Classifier (GSC) were published in The Journal of Clinical Endocrinology & Metabolism (JCEM). The data, from a meta-analysis of 13 independent studies, show that the Afirma GSC can accurately rule out thyroid cancer in patients with indeterminate thyroid nodules (ITNs) and that, when the test identifies a nodule as suspicious, the patient’s risk of malignancy is consistent with, and higher than, that reported in the test’s original clinical validation (CV) study."
Real-world evidence
|
Afirma® Genomic Sequencing Classifier
over1year
Veracyte announces three abstracts to be presented at SITC 2022 annual meeting (Veracyte Press Release)
"Veracyte...announced today that three abstracts highlighting the company’s unique, multi-omics immuno-oncology capabilities and offerings will be presented at the Society for Immunotherapy of Cancer’s 37th Annual Meeting & Pre-Conference Programs (SITC 2022), taking place November 8-12, 2022, in Boston."
Clinical data
|
Brightplex® MDSC Assay • Immunoscore® TCE test
over1year
New Data Suggest Decipher GRID-Derived Genomic Signature Can Help Identify Men with Prostate Cancer Who Should Receive High-Dose Radiotherapy (Businesswire)
P3 | N=350 | NCT01272050 | "The new data shared at ASTRO show that the subset of men with higher PORTOS scores had substantial improvement in clinical-progression-free survival (CPFS) with the higher dose of SRT (70Gy). Specifically, those men with higher PORTOS scores had an absolute benefit of 45% CPFS at 5 years with dose-intensified SRT compared with the standard dose, while the men with lower PORTOS scores had an absolute benefit of -10% (p-interaction=0.003)....It is estimated that up to 40 percent of men with intermediate- or high-risk prostate cancer may experience a biochemical disease recurrence after RP, which is characterized by rising levels of serum prostate-specific antigen (PSA).1 For those men who experience a rising PSA, treatment with 64-72 Gy SRT is now standard of care, though treatment with higher doses can lead to greater urinary and bowel side effects."
P3 data
over1year
Veracyte Data Presented at ATA Annual Meeting Provide New Insights into Molecular Underpinnings of Thyroid Cancer (Businesswire)
"Veracyte, Inc...announced data that provide new insights into thyroid tumor behavior....They found that the top-performing signatures were able to stratify nodules as low-risk with a negative predictive value for no invasion or metastasis of 95% and 100%, respectively. Conversely, the highest-performing signatures had a positive predictive value of 57% for invasion and 41% for metastasis....Additional data presented at the ATA conference demonstrate the Afirma GSC’s ability to inform diagnosis and treatment decisions for patients with thyroid nodules. While thyroid stimulating hormone receptor (TSHR) mutations are mostly associated with benign thyroid nodules, researchers found that when the Afirma GSC identified a thyroid nodule with a TSHR mutation and a result that was 'suspicious' for cancer, the risk of malignancy was significantly higher at 15.3%, compared to those classified by the Afirma GSC as benign where the extrapolated risk is <1.5%."
Clinical data
|
Afirma® Genomic Sequencing Classifier
over1year
New data presented at CHEST 2022 reinforce clinical value of Veracyte’s genomic tests in interstitial lung disease and lung cancer (Veracyte Press Release)
"Veracyte...announced that two abstracts highlighting the clinical value of the company’s Envisia Genomic Classifier and Percepta Nasal Swab tests in interstitial lung disease (ILD) and lung cancer, respectively, were presented as posters today at the American College of Chest Physicians (CHEST) Annual Meeting 2022, taking place in Nashville, Tenn., October 16-19."
Clinical data
over1year
New data published in JNCI demonstrate Veracyte’s Decipher Prostate Genomic Classifier may improve identification of aggressive prostate cancer in African American men (Businesswire)
"Veracyte...announced that data published today in the Journal of the National Cancer Institute demonstrate that the company’s Decipher Prostate Genomic Classifier may help identify African American men with early, localized prostate cancer who are most likely to harbor more aggressive disease. The data, from the prospective, multi-site VANDAAM Phase 2 clinical study, suggest that the genomic test may offer a robust improvement over clinical factors alone in risk-stratifying prostate cancer among African American men, which may help reduce disparities in prostate cancer outcomes."
Clinical data
|
Decipher Prostate Cancer Test